EUVIMEDEUVIMED entdecken
Multizentrische Studie

Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry

Eva Katharina Messer iD, David Petroff, Jörn Schattenberg, Stefan Zeuzem, Manfred von der Ohe, Leopold Ludwig iD, Münevver Demir, Peter Buggisch, Kerstin Stein, Yvonne Serfert, Heiner Wedemeyer, Thomas Berg und 3 weitere

Zeitschrift für Gastroenterologie · 01.08.2025 · 63 (08) · 836-843

DOI: 10.1055/a-2592-6109 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.08.2025. Verfasst von Eva Katharina Messer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany. Hauptthemen laut MEDLINE: Eligibility Determination, Registries, Fatty Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The THR-β agonist resmetirom is the first treatment approved for metabolic dysfunction-associated steatohepatitis (MASH) in the US so far. It can be prescribed given MASH and F2/F3-fibrosis (“at-risk MASH”). We analyzed how many patients qualify for resmetirom in a recently recruited Steatotic Liver Disease-cohort involving both tertiary and secondary care centers, the German SLD-Registry. Indication for resmetirom was assessed by three different approaches: (i) biopsy-proven MASH with F2/3 fibrosis and NAS-score ≥ 4; (ii) FibroScan-AST (FAST) score ≥ 0.67 and vibration controlled transient elastography (VCTE) < 15 kPa; (iii) US expert recommendations with VCTE 10–15 kPa and platelets ≥ 140×109/L or VCTE 8–15 kPa. 1113 patients were recruited across 8 tertiary and 12 secondary care centers. NAS grading and staging were available for 180 cases (16%) with 179/180 conducted at tertiary care level. Of these, 61 (34%) qualified for resmetirom. FAST score without histologic assessment was available for 638 cases (57.3%), of which 612 (87%) were from tertiary and 26 (11%) from secondary care centers. Based on approach (ii), 41 (6%) of these individuals qualified for resmetirom compared to 117 (18.3%) using approach (iii). Combining approach (iii) with FAST ≥ 0.67 leads to 191 (30.0%) eligible patients. Using VCTE 8–15 kPa results in 182 (28.5%) eligible patients. Eligibility for resmetirom treatment depends on the available method used to identify “at-risk MASH”. Availability of VCTE was highest among different levels of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eligibility DeterminationRegistriesFatty LiverHumansGermanyMaleFemaleMiddle AgedAgedElasticity Imaging TechniquesAdultTreatment OutcomeReproducibility of ResultsSensitivity and SpecificityRisk Factors

Autor:innen und Institutionen

  • Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
  • Clinical Trial Centre Leipzig, Leipzig University, Leipzig, Germany, Leipzig, Germany.
  • Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany.
  • Medical Clinic I, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.
  • Gastroenterologische Studiengesellschaft Herne, Herne, Germany.
  • Praxis Ludwig & Güthle, Dornstadt, Germany.

ORCID-Profile: Eva Katharina Messer, Leopold Ludwig, Johannes Wiegand

Zitieren

APA

Messer, E. K., Petroff, D., Schattenberg, J., Zeuzem, S., von der Ohe, M., Ludwig, L., Demir, M., Buggisch, P., Stein, K., Serfert, Y., Wedemeyer, H., Berg, T., Hofmann, W. P., Geier, A., & Wiegand, J. (2025). Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry. Zeitschrift für Gastroenterologie, 63(08), 836-843. https://doi.org/10.1055/a-2592-6109

Vancouver

Messer EK, Petroff D, Schattenberg J, Zeuzem S, von der Ohe M, Ludwig L, et al. Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry. Zeitschrift für Gastroenterologie. 2025;63(08):836-843. doi:10.1055/a-2592-6109

BibTeX
@article{Messer2025,
  author = {Messer, Eva Katharina and Petroff, David and Schattenberg, Jörn and Zeuzem, Stefan and von der Ohe, Manfred and Ludwig, Leopold and Demir, Münevver and Buggisch, Peter and Stein, Kerstin and Serfert, Yvonne and Wedemeyer, Heiner and Berg, Thomas and Hofmann, Wolf P and Geier, Andreas and Wiegand, Johannes},
  title = {Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2025},
  volume = {63},
  number = {08},
  pages = {836--843},
  doi = {10.1055/a-2592-6109}
}
Kostenlos starten →